ArticleApplied microbiology and biotechnology2026
Biogenic synthesis and characterization of selenium nanoparticles by halotolerant Bacillus sonorensis 2MNHR.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selenium nanoparticles (SeNPs) have attracted significant attention owing to their unique physicochemical properties and promising biomedical applications. In the present study, a newly isolated halotolerant marine Bacillus sonorensis 2MNHR strain was employed for the extracellular biosynthesis of SeNPs. Bacterial isolates capable of reducing selenium oxyanions were obtained from seawater samples collected at Alexandria Harbor, Mediterranean Sea, Egypt. The ability of ten morphologically distinct bacterial isolates to reduce sodium selenite and sodium selenate under aerobic conditions was evaluated. Among them, only one isolate consistently reduced sodium selenite, as evidenced by the development of a characteristic red coloration in both liquid and solid media within 72 h, whereas no reduction was observed with sodium selenate. Extracellular reduction was confirmed using a cell-free supernatant assay. UV-Vis and FTIR analyses of the filtrate confirmed the involvement of biomolecules in selenite biotransformation, while GC-MS analysis revealed diverse organic compounds potentially responsible for reduction and stabilization. The biosynthesized SeNPs were comprehensively characterized using UV-visible spectroscopy, Fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), zeta potential analysis, scanning electron microscopy coupled with energy-dispersive X-ray spectroscopy (SEM-EDX), and transmission electron microscopy (TEM). These analyses confirmed the formation of spherical, amorphous nanoparticles with sizes ranging from 80 to 200 nm (average ~ 160 nm) and a characteristic UV-Vis peak at 226 nm. A zeta potential of -38 mV indicated high colloidal stability. The SeNPs exhibited strong antimicrobial activity, with inhibition zones ranging from 23 to 32 mm and MIC values from 19.5 to 156.25 µg/mL. MBC/MIC ratios (≤ 2) confirmed bactericidal activity against most tested bacteria, while a ratio of 4 indicated borderline activity against Pseudomonas aeruginosa and fungistatic behavior against Candida albicans. These findings highlight the potential of halotolerant marine bacteria as sustainable platforms for the production of stable and biologically active SeNPs. KEY POINTS: • Isolation of marine Bacillus sonorensis 2MNHR with high selenite-reducing potential • Efficient extracellular biosynthesis of stable selenium nanoparticles (SeNPs) • Integrated physicochemical characterization and antimicrobial evaluation of SeNPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.